Skip to content
★ Sign in to follow
TD
Total declarations
26
Company
1
▲ Purchases (2 ops.)
€29k
▼ Sales (11 ops.)
€1.1M

Latest filing published 07 Jan 2020 for Precigen, INC..

Filing timeline

BuySale
Thomas D. Reed

Insider track record

Disclosed buys
2
Disclosed sells
11
Signal history

Closed purchases

Market purchases
2
Positive at T+90
50%
Median T+90
-0.9%

Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 13 May 2014 · 4563 days ago · €7,283
    +120.2%
    Entry US$17.39 · Close at T+365 US$38.31
  • Filed 15 Aug 2013 · 4834 days ago · €22k
    -16.9%
    Entry US$24.79 · Close at T+365 US$20.60

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Thomas D. Reed: trading record in brief

All filings by Thomas D. Reed on record concern Precigen, Inc. We count 26 filings; the first trade dates from 13 August 2013 and the latest from 6 January 2020.

Market trades split into 2 purchases (€29k) and 11 sales (€1.1M). Sales outweigh purchases by €1.1M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 2 share grants and 9 option exercises. So far in 2020, the count stands at no purchases and 3 sales.

The record was last updated on 7 January 2020 with an open-market sale (€28k) in Precigen, Inc. The last purchase on record was published on 13 May 2014, which is 4,563 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.

Companies and markets linked to Thomas D. Reed

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations26 total
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    18,940 sharesCommon StockSEC:0001123292-20-000111:0
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    31,575 USD29SEC
    5,416 shares@ US$5.832.5% of flowCommon StockSEC:0001123292-20-000111:1
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    9,766 sharesCommon StockSEC:0001123292-20-000068:0
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    17,229 USD29SEC
    2,986 shares@ US$5.771.4% of flowCommon StockSEC:0001123292-20-000068:1
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    19,785 USD29SEC
    3,533 shares@ US$5.601.6% of flowCommon StockSEC:0001123292-20-000041:1
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    14,340 sharesCommon StockSEC:0001123292-20-000041:0
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    14,341 sharesCommon StockSEC:0001123292-19-001191:0
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    20,119 USD29SEC
    3,658 shares@ US$5.501.6% of flowCommon StockSEC:0001123292-19-001191:1
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    14,341 sharesCommon StockSEC:0001123292-19-000963:0
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    27,370 USD29SEC
    3,527 shares@ US$7.762.1% of flowCommon StockSEC:0001123292-19-000963:1
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    69,960 USD12SEC
    16,500 shares@ US$4.245.4% of flowCommon StockSEC:0001123292-19-000444:0
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    688,050 USD16SEC
    165,000 shares@ US$4.1753.2% of flowCommon StockSEC:0001123292-19-000444:1
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    185,680 USD12SEC
    44,000 shares@ US$4.2214.4% of flowCommon StockSEC:0001123292-19-000444:2
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    10,718 USD11SEC
    2,300 shares@ US$4.660.8% of flowCommon StockSEC:0001123292-19-000444:3
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    9,412 USD11SEC
    2,969 shares@ US$3.170.7% of flowCommon StockSEC:0001123292-19-000231:0
  • ◆
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    13,774 sharesCommon StockSEC:0001123292-19-000128:0
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    9,766 sharesCommon StockSEC:0001123292-19-000085:0
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    20,814 USD29SEC
    2,944 shares@ US$7.071.6% of flowCommon StockSEC:0001123292-19-000085:1
  • ▼
    Chief Science OfficerExecutivesPrecigen, Inc.
    190,800 USD12SEC
    30,000 shares@ US$6.3614.7% of flowCommon StockSEC:0001123292-19-000030:0
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    78,387 USD12SEC
    29,692 shares@ US$2.645.4% of flowCommon StockSEC:0001225385-17-000108:0
  • ◇
    Chief Science OfficerExecutivesPrecigen, Inc.
    23,512 USD11SEC
    8,906 shares@ US$2.641.6% of flowCommon StockSEC:0001225385-17-000108:1
  • ◆
    Chief Science OfficerExecutivesPrecigen, Inc.
    82,711 USD0SEC
    64,117 shares@ US$1.29Common StockSEC:0001356090-15-000072:0
  • ▲
    Chief Science OfficerExecutivesPrecigen, Inc.
    9,984 USD0SEC
    640 shares@ US$15.60Common StockSEC:0001498902-14-000062:0
    Canonical exit: 11 Aug 2014 (T+90)
  • ●
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    845 shares0Common StockSEC:0001498902-13-000050:0
  • ●
    Chief Science OfficerExecutivesPrecigen, Inc.
    0SEC
    55 shares0Common StockSEC:0001498902-13-000050:1

25 of 26 declarations